Advanced searches left 3/3

Placebo - PubMed

Summarized by Plex Scholar
Last Updated: 26 September 2022

* If you want to update the article please login/register

Expectations: How and when do they contribute to placebo analgesia?

Optimisation is one of the most significant subjective variables in placebo research, and in placebo research, hopes are cited as one of the most important subjective variables. While some studies have shown a correlation between hopes and pain relief, some haven't. Participants in placebo trials rate their satisfaction when asked to rate them on a scale in advance, but are less likely to reveal their prior findings in unprompted manner, often expressing prior belief or wishes of recovery. The results point to the fact that placebo effects are associated with placebo effects, particularly in placebo analgesia.

Source link: https://doi.org/10.3389/fpsyt.2022.817179


The effects of oral and vaporized cannabis alone, and in combination with alcohol, on driving performance using the STISIM driving simulator: A two-part, double-blind, double-dummy, placebo-controlled, randomized crossover clinical laboratory protocol.

The legalization of cannabis for medicinal and non-medicinal uses, as well as an increase in the availability of cannabis-based products, has created urgent need for cannabis regulatory science. Participants in each study will complete seven experimental sessions during which acute doses of placebo or high u03949-THC cannabis containing 0, 10, or 25 mg will be administered both alone and in combination with placebo or alcohol-containing beverages. This paper is intended to extend previous studies of cannabis and alcohol's driving results by using oral and vaporized routes of cannabis administration. This data may help improve understanding of impairment due to co-use of alcohol and these new forms of cannabis, as well as education of the general population of cannabis and/or alcohol use.

Source link: https://doi.org/10.3389/fphar.2022.964749


Randomized, placebo-controlled, single-blind phase 1 studies of the safety, tolerability, and pharmacokinetics of BRII-196 and BRII-198, SARS-CoV-2 spike-targeting monoclonal antibodies with an extended half-life in healthy adults.

Background: BRII-196 and BRII-198 are two anti-SARS-CoV-2 monoclonal neutralizing antibodies used as a cocktail therapy for treating COVID-19, which has been modified Fc region with a half-life. A single intravenous infusion of single BRII-196 or BRII-198 up to 3,000 mg, or BRII-196 and BRII-198 combination up to 1500/1500 mg, or placebo, was administered for 180 days. As exploratory endpoints, plasma neutralization activities against SARS-CoV-2 Delta live virus in comparison to post-vaccination plasma were evaluated against as exploratory endpoints. BRII-196 and BRII-198 demonstrated pharmacokinetics typical of Fc-engineered human IgG1 with mean terminal half-lives of 44. 6-48. 6 days and 72. 2-83. 0 days, respectively, with no signs of interaction or significant anti-drug antibody formation, respectively. In plasma samples obtained on day 180 post-infusion, neutrophilizing activities against the live virus of the SARS-CoV-2 Delta variant were maintained.

Source link: https://doi.org/10.3389/fphar.2022.983505


Modeling the Probability of HIV Infection over Time in High-Risk Seronegative Participants Receiving Placebo in Five Randomized Double-Blind Placebo-Controlled HIV Pre-Exposure Prophylaxis Trials: A Patient-Level Pooled Analysis.

Using NONMEM7. 4 The risk of HIV infection with time was determined over time. In the risk of infection among and within trial populations, we identified predictors of HIV risk and discovered a significant difference in the risk of infection among and within trial populations, with each study including a mixture of low, moderate, and high-risk individuals. Persons who were female at birth were at a higher risk of HIV infection than those who were not male at birth were at a greater risk of HIV infection than those who were male at birth.

Source link: https://doi.org/10.3390/pharmaceutics14091801


A Hot Water Extract of Curcuma longa L. Improves Fasting Serum Glucose Levels in Participants with Low-Grade Inflammation: Reanalysis of Data from Two Randomized, Double-Blind, Placebo-Controlled Trials.

Chronic low-grade inflammation is linked to glucose homeostasis disruption, but the effect of C. longa extract on human glucose metabolism is unclear. Participants were given either a hot water extract from C. longa or without C. longa extract for a ten-week course, and we determined serum hsCRP and fasting serum glucose in both studies. In either study, we found no significant difference in fasting serum glucose levels between the two groups, but in the high-hsCRP subgroup, the C. longa extract group had significantly lower serum hsCRP and fasting serum glucose levels than the placebo group, but in the high-hsCRP subgroup, we had significantly lower serum hsCRP and fasting serum glucose in comparison to the placebo group. In conclusion, a hot water extract of C. longa may help to increase systemic glucose metabolism in people with persistent low-grade inflammation.

Source link: https://doi.org/10.3390/nu14183763


The Effects of Spirulina maxima Extract on Memory Improvement in Those with Mild Cognitive Impairment: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

Spirulina maxima, a marine microalga that has been sold around the world as a super food, is a marine microalga. This research was done to determine the ability of memory enhancement in the elderly adults using Spirulina maxima 70% ethanol extract. 80 volunteers were randomly divided into two groups at Jeonju, Republic of Korea, who were randomly assigned to two groups in this random, double-blind, placebo-controlled clinical trial. The participants were tested at baseline and after a 12-week period to see whether there were any improvements in their visual learning, visual working memory, and verbal learning tests from the Korean version of the Montreal Cognitive Assessment, brain-derived neurotrophic factor and total antioxidant capacity, as well as total antioxidant capacity. The intervention group showed a significant increase in visual learning and visual working memory test results as well as increased vocabulary relative to the placebo group. SM70EE may have a role in the care of dementia patients.

Source link: https://doi.org/10.3390/nu14183714


The Effect of Anaerobically Cultivated Human Intestinal Microbiota Compared to Fecal Microbiota Transplantation on Gut Microbiota Profile and Symptoms of Irritable Bowel Syndrome, a Double-Blind Placebo-Controlled Study.

Healthy donors have been shown to improve the signs of irritable bowel syndrome and altered the recipient's's gut microbiota profile. Alternatively, anaerobically grown human intestinal microbiota can be used to alter the gut microbiota. The purpose of the current research was to compare the toxicity and safety of ACHIM suspension with donor-FMT and placebo to treat IBS. Actinobacteria spp. was the most relevant for IBS patients for Bacterial strain signals in IBS patients. After receiving donor-FMT compared to placebo and on Alistipes onderdonkii before and after treatment in the subgroups of ACHIM and donor-FMT vs. placebo, the subgroups of ACHIM and donor-FMT were compared to placebo and in the case of placebo and on Alistipes onderdonkii before and after therapy. ACHIM and donor-FMT were significantly different from placebo and placebo, according to some bacterial strain signals.

Source link: https://doi.org/10.3390/microorganisms10091819


Lactulose Ingestion Induces a Rapid Increase in Genus Bifidobacterium in Healthy Japanese: A Randomised, Double-Blind, Placebo-Controlled Crossover Trial.

The presence of genus Bifidobacterium in the large intestine can be increased by a low dose of lactulose in the large intestine, but the exacts of the daily variation of Bifidobacterium in the Bifidobacterium have yet to be established. The number of Bifidobacterium in the lactulose-treatment group was already elevated 2 days after beginning lactulose ingestion than in the placebo group. With ingestion of 4 g lactulose/day for two weeks, there were significant rises in the number and number of Bifidobacterium, but there were no significant changes in the intestinal microbiota between lactulose and placebo ingestion.

Source link: https://doi.org/10.3390/microorganisms10091719


Coenzyme Q10 Supplementation in Statin Treated Patients: A Double-Blinded Randomized Placebo-Controlled Trial.

Patients treated with statins do not have a CoQ10-based diet or mitochondrial function. To see if changes in muscle CoQ10 levels and mitochondrial function rises the muscle CoQ10 levels and improves mitochondrial function, and mitochondrial function, and if changes in muscle CoQ10 levels correlate with changes in myalgia's intensity. 37 men and women in simvastatin therapy with and without myalgia were randomly assigned to receive 400 mg CoQ10 daily or matched placebo tablets for eight weeks.

Source link: https://doi.org/10.3390/antiox11091698

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions